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ABSTRACT 
 
BACKGROUND 
The 2014 American Heart Association/American College of Cardiology Valvular Heart Disease 
Guidelines state that mitral valve diseases should be repaired at a Center of Excellence (CoE). 
We evaluate the cost-effectiveness of such referrals.  
METHODS 
We estimate patients’ life expectancy based on projected survival of patients after mitral valve 
surgery and develop a cost model to calculate short- and long-term benefits and costs to both 
patients and payers. Benefits include increased life expectancy and avoidance of medical 
complications for patients. Short-term costs include all upfront payments by patients and payers 
at the time of discharge. Long-term costs include all payments associated with the condition that 
prompted the surgical procedure incurred during the remainder of a patient’s life. We assess 
cost-effectiveness of treating patients with various ages and major comorbidities at CoEs vs non-
CoEs.   
 Electronic copy available at: http://ssrn.com/abstract=2611186 
RESULTS 
Full implementation of the guidelines would result in an increase in the percentage of patients 
obtaining mitral valve repair instead of valve replacement from 58% to 72%.  Depending on the 
patient’s age and comorbidities, it would also result in a 6.64% to 12.47% reduction in mortality, 
7.85% to 9.97% reduction in reoperation, 9.97% to 17.16% reduction in stroke, and an average 
gain of 3.77 to 9.88 months of life expectancy. Finally, greater reliance on CoEs results in 
financial savings to payers, due to avoidance of the costs of future complications. 
CONCLUSION 
Patients benefit from mitral valve surgery at a CoE regardless of their age or comorbidities. 
Payers may incur additional short-term costs when patients are referred to a CoE, but these are 
fully offset by long-term savings at the current repair rate gap of 24% between CoEs and non-
CoEs in New York State. Redesigning co-pay structures and/or refining the set of patients who 
are referred to CoEs could further align the incentives of patients and payers on a case-by-case 
basis and achieve an even more desirable social outcome.  
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Mitral valve disease is one of the most common forms of heart valve diseases in US, affecting 5% 
of the population and resulting in 500,000 hospital admissions per year.i Mitral valve repair and 
replacement are two different cardiac surgical operations used to treat stenosis or regurgitation of 
the mitral valve. Existing literature indicates that mitral valve repair is superior to mitral valve 
replacement for degenerative mitral insufficiency because it offers better survival, fewer 
complications and lower costs.1,2,3,4  
For purposes of our analysis, we define a Center of Excellence (CoE) as a medical center whose 
repair rate is statistically significantly higher than state or national average. Six hospitals are 
identified as CoEs in New York relative to the state average (see Figure S1 in the Supplementary 
Appendix).5 Despite the strong reputation of CoEs, our analysis of 2,718 patients with elective 
mitral valve diseases in New York from 2009-2012 shows that only 40.4% were treated at a CoE 
for mitral valve surgery. We estimate the average risk-adjusted repair rate to be 70% at CoEs and 
46% at non-CoEs, which implies that 389 patients who could have had their mitral valve repaired 
instead received a less desirable valve replacement.  
Recently, the 2014 American Heart Association/American College of Cardiology Valvular Heart 
Disease Guidelines called for referrals of patients to a CoE for a higher chance of repair.ii The 
main objective of this study is to estimate the incremental health gains as well as costs and 
benefits to payers of this type of referral strategy. 
 
                                                          
i http://heartvalvedisease.nm.org/mitral-valve-disease.html 
ii Thoracic Surgery News, Nov 2014. 
 METHODS 
 
HOSPITAL QUALITY AND PATIENT CHOICE 
This study uses data from the New York State Inpatient Database, which includes 10 million 
discharges from all hospitals in New York State between 2009 and 2012. We identified 
discharges related to isolated mitral valve procedures through its clinical codes 35.12, 35.13 and 
35.24 based on International Classification of Disease (9th revision) and focused on only elective 
cases. Patients were excluded if they were less than 30 years old, had coronary revascularization, 
congenital heart disease, excision of ventricular aneurysm, replacement of thoracic aorta, aortic 
fenestration procedure, closed heart valvuloplasty, heart transplant, or other valvular repair or 
replacement.6 Patients were also excluded if they travelled from other states to New York or if 
they were Native American (less than 1% of the sample). This resulted in 2,718 patients treated 
in 35 hospitals over the four year interval.  
To measure the gap in repair rates between CoEs and non-CoEs, we used a probit model with 
procedure type (i.e., repair or replacement) as the dependent variable. Included in the probit 
model were independent variables of patients’ demographics, insurance type and comorbidities. 
Since patients are not randomly assigned to hospitals, we cannot directly compare observed 
repair rates between hospitals. To correct for a potential selection bias if patients who are more 
likely to benefit from a CoE were also more likely to choose a CoE, we constructed a distance-
based instrumental variable, which correlates with the probability of choosing a CoE but not with 
patient characteristics.7  
To understand which factors affect patients’ choices of hospitals, we used a probit model with 
the choice of a CoE vs a non-CoE as the dependent variable. The independent variables are 
patient demographics, insurance type, extra travel distance to the nearest CoE and a dummy 
indicating whether the patient has a local CoE (i.e., within 5 miles to the nearest hospital).  
COST-BENEFIT MODEL 
To evaluate the impact of hospital choice, we constructed a model to characterize short- and 
long-term costs to both patients and payers. Based on the steps and contingencies associated with 
mitral valve diseases (see Figure S2 in the Supplementary Appendix for a schematic), our model 
includes: (1) travel cost, (2) procedure cost, (3) cost of reoperation, (4) cost of stroke, (5) cost of 
bleeding, (6) cost of maintenance (i.e., warfarin for anticoagulation) for mechanical valve 
replacement, and (7) cost of Structural Valve Deterioration (SVD) for biological valve 
replacement. We estimated these costs for patients without comorbidities (which we refer to as 
“standard” patients) and for patients with common comorbidities, including heart failure, chronic 
lung disease, diabetes, hypertension, renal disease, and atrial fibrillation.4 
We calculated costs to patients associated with treatment in a given hospital as: 
Costs to Patients = Cost of Operative Mortality + Cost of Long-term Survival + Cost of             
Reoperation + Cost of Stroke + Cost of Bleeding + Cost of Maintenance + Cost of SVD + 
Travel Cost  
where each term is measured as the expected change in Quality Adjusted Life Years (QALY) 
induced by the procedure.  For example, Cost of Operative Mortality refers to expected loss of 
QALY caused by the possible outcome of operative death.  
Similarly, we computed costs to payers as: 
Costs to Payers = Procedure Cost + Cost of Reoperation + Cost of Stroke + Cost of Bleeding + 
Cost of Maintenance + Cost of SVD  
where costs over time were converted to net present value of payments using a 5% discount 
rate.iii 
Finally, for both patients and payers, we computed the net benefit from a CoE as the difference 
between the expected cost at a non-CoE hospital and that at a CoE.   
MODEL ELEMENTS 
Because no single source or paper contains all the data required in our model, we drew from 
several sources in the medical literature to estimate the needed parameters. When necessary, we 
supplemented the literature review with estimates from existing datasets including Society of 
Thoracic Surgeons (STS) National Database and National Inpatient Sample Data. All costs and 
benefits were converted into 2014 US dollars. Table 1 summarizes the sources for each model 
element for patients of different ages, with and without comorbidities.  
  
                                                          
iii http://www.irs.gov/irb/2014-47_IRB/ar12.html 
Table 1. Sources of Model Elements 
Model Elements  Resources* 
Repair Rate Daneshmand et al. 20102, Vassileva et al. 20134 
Operative Mortality STS Risk Calculator, NIS 2008-2012† 
Long-term Survival Ray et al. 20068, Daneshmand et al. 20102, Gelsomino et al. 20119, 
Daneshmand et al. 200910 
Procedure-related Reoperation Dumon et al. 200711, STS Risk Calculator 
Stroke Russo et al. 200812,  
National Institute of Neurological Disorders and Stroke 
Bleeding Keneko et al. 201413, Chikwe et al. 201114, Ailawadi et al. 200815,  
LaPar et al. 20103 
Maintenance  http://health.costhelper.com/valve-replacement.html 
Structural Valve Deterioration Bourguignon et al. 201416 
Procedure Cost Medicare Provider Utilization and Payment Data, NIS 2008-2012 
Travel Cost Paulsen et al. 201517 
*A detailed literature review is provided in the Supplementary Appendix. 
†STS Risk Calculator incorporates the STS risk models that are designed to serve as statistical tools to account for the impact 
of patient risk factors on operative mortality and morbidity. National Inpatient Sample database is the largest U.S. database 
of inpatient hospitals that incorporates data from all payers.   
 
 
RESULTS 
HOSPITAL QUALITY 
The likelihood of receiving a repair is influenced by both hospital and patient characteristics. By 
definition CoEs had significantly higher repair rates (Table 2, middle column).  After correcting 
for potential selection bias, our analysis shows that visiting a CoE instead of a non-CoE resulted 
in an average increase in the probability of mitral valve repair of around 24%. However, several 
patient characteristics, including old age, female gender, chronic lung disease, diabetes, and renal 
failure directly reduced the chance of mitral valve repair. Other patient characteristics, such as 
non-white race and having Medicare or Medicaid coverage, reduced the likelihood of receiving a 
mitral valve repair indirectly by reducing the probability of choosing a CoE.  
Table 2. Impact of Patient Characteristics, Comorbidities, Payer and Distance  
  
 
On MV Repair Rate† 
 
On Choice of A CoE†† 
Category Variables Coeff. 
 
S.E. 
 
  Coeff. S.E. 
Demographics  Age -0.019 *** 0.003 
 
-0.005 
 
0.003 
  Female -0.281 *** 0.052 
 
0.001  0.054 
  Black -0.236 ** 0.101 
 
-0.180 * 0.103 
  Hispanic -0.367 *** 0.117 
 
-0.291 ** 0.121 
  Asian -0.455 ** 0.191 
 
-0.528 *** 0.193 
  Others -0.061 
 
0.090 
 
0.552 *** 0.081 
Payer Medicare -0.163 ** 0.074 
 
-0.184 ** 0.077 
  Medicaid -0.251 ** 0.109 
 
-0.518 *** 0.114 
  Self -0.536 
 
0.341 
 
-0.217  0.374 
  Other 0.284 
 
0.197 
 
-1.068 *** 0.263 
Comorbidities  Heart Failure -0.103 
 
0.326 
 
0.000  0.328 
  Lung Disease -0.229 *** 0.068 
 
0.110  0.073 
  Diabetes -0.180 *** 0.069 
 
-0.048  0.074 
  Hypertension 0.074 
 
0.054 
 
-0.045  0.056 
  Renal Disease -0.256 *** 0.087 
 
-0.089  0.094 
 Atrial Fibrillation -0.100 * 0.053  0.011  0.055 
Proximity Extra Dist. to CoE 
  
  
 
-0.025 *** 0.002 
  CoE in 5 Miles 
  
  
 
0.202 *** 0.066 
CoE 
 
0.724 *** 0.140 
    
  Constant 1.521 *** 0.183   0.483 *** 0.182 
*** p<0.01, ** p<0.05, * p<0.1                                                                                                                                                                          
†A probit model was used for the analysis of MV repair rate. The dependent variable is whether a patient received mitral 
valve repair. Independent variables are patient demographics, insurance type, comorbidities, and a dummy for CoEs. The 
baseline group has the following characteristics: male, white, private insurance, and no comorbidities. Distance is used as an 
instrument for CoEs to correct for the potential selection bias that patients who choose a CoE are also those who are more 
likely to benefit from a CoE.                                                                                                                                                                             
††A probit model was used for the analysis of patient choice of a CoE vs a non-CoE. The dependent variable is whether a 
patient chose a CoE. Independent variables are patient demographics, insurance type, comorbidities, distance and proximity 
to a CoE. The baseline group has the following characteristics: male, white, private insurance, no comorbidities, and no CoE 
in 5 miles.                                                                                                                                                                                                                                                                          
 
PATIENT CHOICE 
Among the 2,718 patients in our analysis, 1,097 (40.4%) chose a CoE (see Table 3). This 
percentage strongly correlates with patients’ distance to the nearest CoE, suggesting distance is 
an important factor affecting how patients chose hospitals. Among the 1,154 patients who had a 
CoE within 5 miles from their nearest hospital, 61.2% chose a CoE. Among those who did not 
have a CoE within 5 miles from their nearest hospital, only 38.8% chose a CoE. Patients who 
chose CoEs were younger (64.3 vs 65.4, p-value of 0.020). Compared with CoEs, non-CoEs 
treated a higher percentage of white patients (76.8% vs 66.5%, p-value of 0) and Asian patients 
(2.4% vs 1.3%, p-value of 0.037), a higher percentage of patients with Medicare (52.6% vs 
48.0%, p-value of 0.019) and Medicaid (8.4% vs 5.3%, p-value of 0.002), and a lower 
percentage of patients with private insurance (35.8% vs 45.7%, p-value of 0). There was no 
significant difference between CoEs and non-CoEs in terms of patients’ gender.     
Table 3. Characteristics of Patients Treated at CoEs and non-CoEs* 
Variable Non-CoE CoE† P-Value 
Age (mean) 65.4 64.3 0.020 
   Below 50 11.5% (186)‡ 13.5% (148) 0.059 
   50-60 19.8% (321) 21.7% (238) 0.110 
   60-70 27.2% (440) 26.9% (295) 0.439 
   70-80 28.0% (454) 25.4% (279) 0.068 
   Above 80 13.6% (220) 12.5% (137) 0.204 
Gender    
   Female 45.5% (738) 43.8% (481) 0.388 
   Male 54.5% (883) 56.2% (616) 0.388 
Race    
   White 76.8% (1245) 66.5% (730) 0 
   Black 7.8% (127) 7.1% (78) 0.483 
   Hispanic 5.9% (95) 4.3% (47) 0.070 
   Asian 2.4% (39) 1.3% (14) 0.037 
   Other Race 7.1% (115) 20.8% (228) 0 
Payer    
   Medicare 52.6% (853) 48.0% (527) 0.019 
   Medicaid 8.4% (136) 5.3% (58) 0.002 
   Private  35.8% (580) 45.7% (501) 0 
   Self-Payer 0.5% (8) 0.5% (6) 0.849 
   Other 2.7% (44) 0.5% (5) 0 
Extra Distance to CoE     
   Less than 5 miles 29.8% (483) 61.2% (671) 0 
   More than 5 miles 70.2% (1138) 38.8% (426) 0 
Total Number 59.6% (1621)  40.4%(1097)   
*This summary is based on New York State Inpatient Database 2009-2012.  
†This study includes 35 NY hospitals, out of which 6 have risk adjusted repair rates that are significantly higher than the 
average of all hospitals in New York. These six hospitals are called CoEs in this study. 
‡Percentage of patients in each age group and number of cases (in bracket).   
 
Table 2 (right column) summarizes the estimation results of the patient choice model and shows 
how patient characteristics, insurance type, travel distance and proximity to a CoE affected the 
likelihood of choosing a CoE. We see that, compared with white patients, Hispanic and Asian 
patients were less likely to choose a CoE. Compared with patients with private insurance 
coverage, those with Medicare, Medicaid and other payers were also less likely to choose a CoE. 
The probability of choosing a CoE decreased as the extra travel distance to the nearest CoE 
increased. Whether a patient had a local CoE significantly affected his/her likelihood of choosing 
a CoE. But we did not find gender and comorbidities to play a significant role in affecting 
patients’ choice of a CoE. 
LIFE EXPECTANCY  
Our model estimates that the life expectancy a patient gained from going to a CoE instead of a 
non-CoE ranged from 3.77-9.88 months depending on the patient’s age and comorbidities (Table 
4, top). Generally speaking, patients in their 70s benefited the most. However, existence of 
comorbidities reduced the benefits from a CoE for all age groups. The relationship between 
patients’ age and benefits is not linear, because younger patients were more likely to receive a 
mechanical valve replacement, which is both more durable and more hazardous (with respect to 
stroke risk) than a biological valve. 
We converted life expectancy into monetary value using the formula 1000k × age-0.66.18 For 
patients with mitral valve replacement, this number was further discounted by yearly mortality 
rates associated with biological or mechanical valve replacement. The results are summarized in 
Table 4 (middle). This shows that patients’ benefit ranged from $7,548 (for patients in their 80s 
with heart failure) to $28,508 (for patients in their 70s with no comorbidities).  
Table 4. Savings to Patients and Payers* 
  Age Group 
Comorbidities 50 60 70 80 
Patient Life Expectancy (mo)** 
   
  
Standard 7.86 8.46 9.88 7.77 
Hypertension 7.68 8.06 8.91 6.68 
Heart Failure 5.43 6.34 5.35 3.77 
Diabetes 6.14 6.37 7.11 5.18 
Renal Disease 6.15 5.76 6.66 3.81 
Atrial Fibrillation 5.64 5.54 5.77 4.10 
Chronic Lung 5.97 6.28 7.08 5.24 
Patient Monetary Savings† 
   
  
Standard $23,857 $25,299 $28,508 $20,789 
Hypertension $24,443 $24,356 $25,556 $17,264 
Heart Failure $16,454 $18,407 $13,923 $7,548 
Diabetes $18,150 $18,384 $19,459 $12,497 
Renal Disease $18,684 $16,627 $15,609 $8,455 
Atrial Fibrillation $17,084 $16,018 $15,358 $8,732 
Chronic Lung $17,319 $17,906 $19,148 $12,747 
Payer Monetary Savings‡ 
Standard $8,075 $7,076 $4,452 $2,417 
Hypertension $7,846 $6,846 $4,259 $2,158 
Heart Failure $6,903 $6,353 $4,239 $2,590 
Diabetes $5,708 $4,976 $2,879 $1,231 
Renal Disease $5,695 $4,939 $2,885 $1,379 
Atrial Fibrillation $6,348 $5,797 $3,635 $2,026 
Chronic Lung $5,699 $4,941 $2,889 $1,382 
*All results are based on our findings that average repair rate of CoEs is 24% higher than that of non-CoEs. Related risk 
factors include operative mortality, long-term survival, reoperation, stroke, bleeding, maintenance (for mechanical valve) 
and structural valve deterioration (for biological valve). Green color indicates positive savings.  
**Increase in life expectancy refers to the difference between life expectancy at CoEs and that at non-CoEs.                                                                                                                                                                    
†Conversion of life expectancy to monetary value is based on the formula 1000k × age-0.66. 18                                                                                                                                                                  
‡ Cost to payers refers to the difference between cost at CoEs and that at non-CoEs. We estimate that mitral valve repair 
costs $46,000 and mitral valve replacement costs $53,000 at non-CoE hospitals and both costs are $4,000 higher at CoEs.                                                                                                                                                                          
 
COSTS TO THE PAYERS 
Costs to payers also depend on a patient’s age and comorbidities (Table 6, bottom). Estimating 
these costs by using the sources in Table 1 and our statistical estimates of the increased 
likelihood of receiving a repair from a CoE indicates that payers obtained positive savings 
through treatment at a CoE for patients of all age groups and all comorbidities.  Per patient 
benefit to payers ranged from $1,231 (for patients in their 80s with diabetes) to $8,075 (for 
patients in their 60s with no comorbidities).   
 
 
SOCIETAL BENEFIT 
We calculated societal benefits by adding the net savings to patients and payers (See Table S1 in 
the Supplementary Appendix). Societal benefits were positive for all age groups and all 
comorbidities, ranging from $9,834 (for patients in their 80s with renal disease) to $32,959 (for 
patients in their 70s with no comorbidities).  
 
DISCUSSION 
 
Mitral valve repair is superior to mitral valve replacement for all age groups and all 
comorbidities for isolated degenerative mitral valve disease. Based on inpatient discharge data 
from New York State 2009-2012, our study suggests that CoEs have significantly higher repair 
rates than non-CoEs with an average gap in risk adjusted repair rate of around around 24%. 
Despite this, roughly 60% of patients in the New York cohort failed to choose a CoE, and 
therefore some of them missed the opportunity to receive medically beneficial mitral valve 
repairs. This study shows that distance and insurance type are two important factors affecting 
patients’ choice of a CoE.  
Our model predicts that referral of mitral patients to a CoE as outlined in the 2014 American 
Heart Association/American College of Cardiology Valvular Heart Disease Guidelines would 
benefit patients of all age groups and all comorbidities. However, the net savings vary widely for 
different age groups and different comorbidities, ranging from $7,548 to $28,508.  
Directing patients to CoEs benefits payers as well, because long-term reductions in costs of 
complications are sufficient to offset the higher short-term procedure cost at a CoE. Therefore, 
the economic incentives of patients and payers align (Table 4). Presumably, better dissemination 
of information about the clinical and economic benefits of mitral valve surgery at a CoE would 
result in more of these patients going to a CoE. 
We should note, however, that referring all patients to CoEs, as recommended by the Valvular 
Heart Disease Guidelines, could create longer travel distance and capacity problems for 
treatment at the CoEs. Our model predicts that, if patients were referred to the nearest CoE, 
overall repair rate would increase by 26%, patients would need to travel 11 miles further on 
average, and CoEs would experience 150% increase in volume. Furthermore, encouraging all 
patients to go to CoEs could retard the establishment and maintenance of proficiency of other 
hospitals. 
Finally, the gap of repair rate between CoEs and non-CoEs is not uniform across patients of 
differing levels of case complexity, which suggests that the incentives of patients and payers are 
not necessarily aligned for each individual patient. Better prediction is needed to identify which 
patients are most likely to benefit from the sophistication and experience of a CoE. For instance, 
it may be possible for a cardiologist or surgeon to analyze the preoperative echocardiogram to 
estimate the repairability of a patient’s mitral valve. For purposes of illustration, suppose that 
these estimates are classified into low, moderate and high and that outcome data for hospitals are 
stratified according to these classifications. Then, as illustrated in Figure 1, the repair rate gap 
between CoEs and non-CoEs is likely to be small for the low category (some patients will get 
their mitral valve repaired at a CoE or a non-CoE) and for the high category (some patients with 
unrepairable mitral valve will get a replacement even if they visit a CoE). Hence, neither patients 
in these categories nor their payers will have strong incentives to choose a CoE. But for the 
moderate repairability category, the gap between CoEs and non-CoEs will be sufficiently large to 
result in substantial benefits to both patients and payers. By routing only those patients who 
benefit most to CoEs, the limited capacity of CoEs will be applied in a manner that produces the 
greatest societal value.  
’ 
Figure 1. Mitral Valve Reparability & Quality Gap between CoEs and Non-CoEs 
In conclusion, our results suggest that both patients and payers can benefit from referring mitral 
patients to CoEs. Under current conditions, such referral generally implies an increased short-
term cost premium at CoEs.  But these costs are overweighed by long-term savings to payers and 
substantial gains to patients. Making properly risk and selection bias adjusted outcome data 
widely available will lead to better provider selection, which in turn will result in improved long-
term outcomes and a reduction in medical costs for patients with mitral valve disease.  
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Supplementary Appendix 
 
 
 
                           Figure S1: Mitral Valve Repair Rate of NY Hospitals† 
† This figure is adopted from Wang, Li, Hopp, et al. (2015). A probit model was used for the analysis of MV repair rate. 
The dependent variable is whether a patient received mitral valve repair. Independent variables are patient 
demographics, comorbidities, hospitals’ mitral volume, and hospital dummies. Distance is used as an instrument for 
mitral volume to correct for the potential selection bias that patients who choose high-volume hospitals are also those 
who are more likely to benefit from high-volume hospitals.                                                                                                                                                                    
* Hospitals with indexes 30-35 have repair rates that are significantly higher than the average. These six hospitals are 
called CoEs in this study.                                                                                                                                                                                                                    
 
 
 Figure S2: Related Events and Decision Process for Patients with Mitral Valve Diseases 
 
MODEL ELEMENTS 
There is no single source or paper that provides all the data required in our model. Therefore, we 
drew from several sources in the medical literature to estimate the various parameters. When 
necessary, we supplemented the literature review by estimates from existing datasets including 
Society of Thoracic Surgeons (STS) National Database and National Inpatient Sample Data. All 
costs and benefits have been converted into 2014 US dollars.  
Below we discuss our estimates and sources of each model element for patients of different ages, 
with and without comorbidities. We consider common comorbidities including heart failure, 
chronic lung disease, diabetes, hypertension, and renal disease (Vassileva et al. 2013).1 
Repair Rate: Our estimate of the impact of age on repair rate is based on Daneshmand et al. 
(2010), who studied 2,064 patients that underwent mitral surgeries from 1986 to 2006, and found 
that the probability of using a biological (over mechanical) valve is 20% for patients between 50 
and 60, 36% for patients between 60 and 70, 71% for patients between 70 and 80 and 89% for 
patients above 80.2 Impact of comorbidities on repair rate is estimated based on Vassileva et al. 
(2013), who studied 47,279 fee-for-service beneficiaries > 65 (from Medicare database) that 
underwent primary isolated mitral valve surgeries from 2000 to 2009, and found that the odds 
ratio is 1.23 for hypertension, 0.8 for diabetes, 0.78 for heart failure, 0.78 for chronic obstructive 
pulmonary disease and 0.8 for renal disease.1 
Operative Mortality: Our estimate of operative mortality is based on the STS Risk Calculator, 
which incorporates the STS risk models that are designed to serve as statistical tools to account 
for the impact of patient risk factors on operative mortality and morbidity.i As the STS Risk 
Calculator does not provide separate results for biological and mechanical replacements, we used 
the National Inpatient Sample 2008-2012 to calculate them retrospectively. For patients aged 50-
60, 60-70, 70-80 and over 80, we estimate operative mortality to be 0.24%, 0.44%, 0.79% and 
1.61% for mitral valve repair, 0.37%, 0.36%, 1.03% and 2.91% for mechanical valve 
replacement, and 0.87%, 1.57%, 1.66% and 2.48% for biological valve replacement.  
Long-term Survival: We estimated long-term survival of patients with mitral valve repair based 
on the US Social Security database, assuming that mitral valve repair restores patients’ normal 
life expectancy (Ray et al. 2006).3 Long-term survival associated with mitral valve replacement 
is estimated based on Daneshmand et al. (2010), who found that yearly mortality rate associated 
with biological valve replacement is 1.8 times that associated with mitral valve repair and yearly 
mortality rate associated with mechanical valve replacement is 1.3 times that associated with 
mitral valve repair.2  
                                                          
i For more details, please see http://riskcalc.sts.org/stswebriskcalc/#/. 
We estimated the impact of comorbidities on long-term survival by using the studies of 
Daneshmand et al. (2010), Gelsomino et al. (2011), Daneshmand et al. (2009).2,4,5 The hazard 
ratio is 2.3 for atrial fibrillation, 1.3 for Chronic Obstructive Pulmonary Disease (COPD), 1.2 for 
diabetes, 2.1 for heart failure, 2.48 for renal disease, and 1.37 for hypertension.  
Procedure-related Reoperation: We estimated the likelihood of procedure-related reoperation 
from the results of Dumont et al. (2007), who studied 188 patients that underwent reoperation for 
recurrent mitral regurgitation at the Cleveland Clinic from Jan 1980 to Jan 2005, and reported 
that around 90% of procedure-related reoperations occur in the first year.6 For simplicity, we 
assumed all procedure-related reoperations occur in the first year. We estimated the impact of 
comorbidities on procedure-related reoperation by using the STS Risk Calculator. For patients 
aged 50-60, 60-70, 70-80 and over 80, we estimate procedure-related reoperation rate to be 
4.38%, 5.21%, 6.19% and 7.41% for mitral valve repair, and 6.12%, 7.53%, 9.23% and 11.38% 
for mitral valve replacement.   
Stroke: We estimated stroke rates based on Russo et al. (2008), who studied 1,344 patients that 
underwent mitral surgery at the Mayo Clinic from Jan 1980 to Dec 1995, and reported that (1) 
annual stroke rate is 1.15% for mitral valve repair, 2.7% for mechanical replacement and 1.65% 
for biological replacement; (2) 5-yr ischemic stroke rate is 6.1% for mitral valve repair, 16.1% 
for mechanical replacement and 8% for biological replacement; and (3) 10-yr ischemic stroke 
rate is 9.9% for mitral valve repair, 23.3% for mechanical replacement and 12.2% for biological 
replacement.7 From their results, we calculated the ratio of stroke rates for biological 
replacement vs repair to be 1.65%/1.15%=1.4, and the ratio for mechanical vs biological 
replacement to be 2.7%/1.65%=1.6. 
The impact of comorbidities on stroke was estimated based on National Institute of Neurological 
Disorders and Stroke.ii We estimated the age-adjusted hazard ratio to be 1.3 for diabetes and 2.5 
for both heart failure and atrial fibrillation.  
Bleeding: We estimated the rate of bleeding from Keneko et al. (2014), who studied a total of 
768 patients with age <65 that underwent mitral valve surgeries from Jan 1991 to Jun 2012, and 
reported that there is no significant difference in the frequency of bleeding events between 
mechanical and biological valve replacements for patients younger than 65.8 Chikwe et al. 
(2011), Ailawadi et al. (2008) and LaPar et al. (2010) reported that there is no significant 
difference in bleeding events between mitral valve repair and replacement.9,10,11 Based on 
Keneko et al. (2014), we estimated freedom from major bleeding (same for mitral valve repair 
and replacement) at 5, 10, and 15 years to be 87.2%, 79.2%, and 71.2% respectively.8 We were 
unable to find literature studying impact of comorbidities on bleeding and therefore used the 
same rates regardless of comorbidity.  
Maintenance: We estimated costs of warfarin and associated risk event to be $1,500/yr (paid by 
payers).iii We also assumed that age and co-morbidities do not affect maintenance cost. 
Structural Valve Deterioration (SVD): We estimated SVD rate based on Bourguignon et al. 
(2014), who studied 450 patients that underwent Carpentier-Edwards PERIMOUNT pericardial 
mitral bioprostheses from 1984 to 2011, and reported that the actuarial freedom from structural 
valve deterioration (SVD) at 20 years is 23.7%.12 
                                                          
ii http://www.ninds.nih.gov/disorders/stroke/preventing_stroke.htm 
iii http://health.costhelper.com/valve-replacement.html 
Procedure Cost: We estimated that mitral valve repair costs $46,000 and mitral valve 
replacement costs $53,000 at local non-CoEs, and the costs are $4,000 higher at CoEs, based on 
the Medicare Provider Utilization and Payment Dataiv and National Inpatient Sample 2008-2012.  
Travel Cost: We estimated travel cost to be $2,000 (paid by patient) in addition to loss of life 
years based on a patient survey conducted by the University of Michigan Cardiovascular Center 
(Paulsen, et al. 2015).13 
 
Table S1. Societal Benefits from a CoE* 
  Age Group 
Comorbidities 50 60 70 80 
Standard $31,933 $32,375 $32,959 $23,205 
Hypertension $32,289 $31,202 $29,815 $19,421 
Heart Failure $23,357 $24,760 $18,162 $10,138 
Diabetes $23,859 $23,360 $22,338 $13,728 
Renal Disease $24,379 $21,567 $18,494 $9,834 
Atrial Fibrillation $23,432 $21,815 $18,993 $10,758 
Chronic Lung $23,018 $22,847 $22,038 $14,129 
* Societal benefit is the sum of patient benefits and payer benefits.                                                                                                                                                                                                                                                                           
 
 
 
                                                          
iv http://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/Medicare-Provider-
Charge-Data/Inpatient.html  
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